RO and diagnostic rads are entirely different specialties with different lifestyles and practice differences. This year, carms did fill RO 100% in first round as opposed to many years prior. i had no personal qualms of advising entry to RO for this batch of medical students that approached me. Alternatively, reach out to your local program director and residents and hear what they have to say you can do a quick pubmed search to find canadian rad onc job market survey data that discusses some of this. That being said, the employment data that exists for Canadian ROs I would say is fairly robust and granular and suitable for some of these models as it is a small specialty relatively speaking, so there *may* be less “assumptions” in these models, but there are still some. job market is still tightish, and these of course are projections, and residency is a long ways away, and the same thing has been said in the past (oh things will be better when you graduate). It’s expected that the number of RO residents entering will be increased to meet expected future demand in the coming years
biggest factor affecting employment in canada is in fact is not # graduating but rather utilization rates. there is significant anticipated growth in the canadian market due to demographics, significant retirements due to elderly workforce, and increased indications for RT with oligometastatic dz
#SDN RAD ONC FULL#
if i recall correctly, 90% of canadian grads will have full time employment by 2 yrs out of training, but much fewer grads are seeking work in US in the past few years, consistent with more jobs opening up canadian RO job market has shown continuous slow improvement since I’ve been in med school and during residency My personal take is US is filling up, Canada is getting better. The post Affirm Holdings punished on weak guidance appeared first on Invezz.Taking short break from board prep to attempt to succinctly answer your question with a few points: We continue to expect to achieve sustained profitability run rate, on an adjusted operating income basis, by the end of fiscal 2023. In light of uncertain macro backdrop, we’re approaching our next fiscal year prudently while maintaining our focus on driving responsible growth and continuing to invest in strengthening our leadership position. The full-year GMV outlook was better-than-expected but analysts had called for a higher $1.91 billion in revenue, though. In comparison, experts were at $4.55 billion and $386 million, respectively.Īffirm expects its gross merchandise volume to fall in the range of $20.5 billion to $22 billion this year on up to $1.725 billion in revenue. Affirm Holdings’ future guidanceįor the current financial quarter, the buy now pay later company forecasts up to $4.4 billion of GMV and $345 million to $365 million in revenue. Versus the start of 2022, Affirm shares are now down more than 70%. We remain focused on scaling our network, maintaining attractive unit economics, capturing greater share, and helping our partners grow. While the growth of online commerce is falling back to pre-COVID levels, the secular trend toward adopting honest financial products is gaining momentum. In the earnings press release, CEO Max Levchin said: Active merchants grew sharply from 29,000 only to 235,000.
Lost $186.4 million versus the year-ago $123.4 million.Shares still tanked 15% after the bell on widened loss and weak guidance. Affirm Holdings Inc ( NASDAQ: AFRM) reported better-than-expected revenue for its fiscal fourth quarter on Thursday.
0 kommentar(er)
